BioWorld-Insight-2010-05-17
Pharma Outlicensing: From Opportunism to R&D Funding
Pharma Outlicensing: From Opportunism to R&D Funding
A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying.

